Over the past two decades, malaria-related deaths have reduced substantially, especially in African children. However, the global malaria burden still remains high. The recent emergence of resistance to artemisinin, the backbone of malaria management, could threaten malaria control. Importantly, over the past five years, there has been an upsurge in research in the development of novel antimalarial drugs (and combinations), malaria vaccine and new vector-control strategies that can boost the malaria control programme.
World Health Organization. World Malaria Report 2018, Geneva: WHO, 2018.
2.
QuispeAMPozoEGuerreroE, et al.Plasmodium vivax hospitalizations in a monoendemic malaria region: severe vivax malaria?Am J Trop Med Hyg2014; 91: 11–17.
SeydelKBKampondeniSDValimC, et al.Brain swelling and death in children with cerebral malaria. N Engl J Med2015; 372: 1126–1137.
5.
LeslieTMikhailAMayanI, et al.Overdiagnosis and mistreatment of malaria among febrile patients at primary healthcare level in Afghanistan: observational study. BMJ2012; 345: e4389–e4389.
6.
World Health Organization. Guidelines for the treatment of malaria, 3rd edn. Geneva: WHO Press, 2015.
7.
MasanjaMIMcMorrowMKahigwaE, et al.Health workers’ use of malaria rapid diagnostic tests (RDTs) to guide clinical decision making in rural dispensaries, Tanzania. Am J Trop Med Hyg2010; 83: 1238–1241.
8.
AnsahEKNarh-BanaSAffran-BonfulH, et al.The impact of providing rapid diagnostic malaria tests on fever management in the private retail sector in Ghana: a cluster randomized trial. BMJ2015; 350: h1019–h1019.
9.
EziefulaACBousemaTYeungS, et al.Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. Lancet Infect Dis2014; 14: 130–139.
10.
WhiteNJPukrittayakameeSHienTT, et al.Malaria. Lancet2014; 383: 723–735.
11.
AshleyEADhordaMFairhurstRM, et al.Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med2014; 371: 411–423.
12.
RueangweerayutRPhyoAPUthaisinC, et al.Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Engl J Med2012; 366: 1298–1309.
13.
PhyoAPNkhomaSStepniewskaK, et al.Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet2012; 379: 1960–1966.
14.
TunKMImwongMLwinKM, et al.Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis2015; 15: 415–421.
15.
MénardDKhimNBeghainJ, et al.A worldwide map of Plasmodium falciparum K13-Propeller polymorphisms. N Engl J Med2016; 374: 2453–2464.
16.
AmaratungaCLimPSuonS, et al.Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis2016; 16: 357–365.
17.
WhiteNJDuongTTUthaisinC, et al.Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria. N Engl J Med2016; 375: 1152–1160.
18.
McCarthyJSLothariusJRückleT, et al.Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. Lancet Infect Dis2017; 17: 626–635.
19.
SulyokMRückleTRothA, et al.DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. Lancet Infect Dis2017; 17: 636–644.
20.
West African Network for Clinical Trials of Antimalarial Drugs (WANECAM). Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet2018; 391: 1378–1390.
21.
Llanos-CuentasALacerdaMVRueangweerayutR, et al.Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet2014; 383: 1049–1058.
22.
LacerdaMVGLlanos-CuentasAKrudsoodS, et al.Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med2019; 380: 215–228.
23.
Llanos-CuentasALacerdaMVGHienTT, et al.Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med2019; 380: 229–241.
24.
LandierJParkerDMThuAM, et al.Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme. Lancet2018; 391: 1916–1926.
25.
McGreadyRLeeSJWiladphaingernJ, et al.Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis2012; 12: 388–396.
26.
DesaiMGutmanJL’lanzivaA, et al.Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet2015; 386: 2507–2519.
27.
KakuruAJagannathanPMuhindoMK, et al.Dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy. N Engl J Med2016; 374: 928–939.
28.
PREGACT Study GroupPekyiDAmpromfiAATintoH, et al.Four artemisinin-based treatments in African pregnant women with malaria. N Engl J Med2016; 374: 913–927.
29.
RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet2015; 386: 31–45.
30.
PennyMAVerityRBeverCA, et al.Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet2016; 387: 367–375.
31.
OlotuAFeganGWambuaJ, et al.Seven-year efficacy of RTS,S/AS01 malaria vaccine among young African children. N Engl J Med2016; 374: 2519–2529.
32.
NeafseyDEJuraskaMBedfordT, et al.Genetic diversity and protective efficacy of the RTS,S/AS01 malaria vaccine. N Engl J Med2015; 373: 2025–2037.
33.
BroderickCNadjmBSmithV, et al.Clinical, geographical, and temporal risk factors associated with presentation and outcome of vivax malaria imported into the United Kingdom over 27 years: observational study. BMJ2015; 350: h1703–h1703.
34.
CheckleyAMSmithASmithV, et al.Risk factors for mortality from imported falciparum malaria in the United Kingdom over 20 years: an observational study. BMJ2012; 344: e2116–e2116.
35.
AsidiAN’GuessanRAkogbetoMCurtisCRowlandM. Loss of household protection from use of insecticide-treated nets against pyrethroid-resistant mosquitoes, Benin. Emerg Infect Dis2012; 18: 1101–1106.
36.
ProtopopoffNMoshaJFLukoleE, et al.Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised controlled, two-by-two factorial design trial. Lancet2018; 391: 1577–1588.
37.
TionoABOuédraogoAOuattaraD, et al.Efficacy of Olyset Duo, a bednet containing pyriproxyfen and permethrin, versus a permethrin-only net against clinical malaria in an area with highly pyrethroid-resistant vectors in rural Burkina Faso: a cluster-randomised controlled trial. Lancet2018; 392: 569–580.
SmitMROchomoEOAljayyoussiG, et al.Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): A randomised, double-blind, placebo-controlled trial. Lancet Infect Dis2018; 18: 615–626.
40.
Foy BD, Alout H, Seaman JA, et al. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): A cluster-randomised trial. Lancet 2019. doi: 10.1016/S0140-6736(18)32321-3.
